MAPT and Alzheimer disease: Figure 2 presents the pathological changes and the neurological deficits of the most common mouse transgenic models of AD used in research: Aβ models: PDAPP [19], APP23 [20,21], Tg2576 [22,23], PS2APP [24], APPlon [25], APPswe/PSEN1dE9 [26]; tau models: hTau [27], Thy-Tau22 [28], hTau-AT [29] and multiple transgenic models: 3×Tg-AD [30] and 5xFAD [31]. Although none of these models completely replicates the most important features of human AD, in vivo models provide context and relevance insight into the pathological alterations that define this condition [32,33,34,35,36].